The clinical trial of creatine in ALS represents a significant opportunity in a market with a high unmet need, as there are currently no effective treatments for ALS. With the trial's completion and initial safety data indicating tolerability, there is potential for further development and commercialization. The competitive landscape includes existing therapies like riluzole, but creatine's novel mechanism may provide a complementary approach. Stakeholders should assess the potential for partnerships or licensing agreements, particularly with organizations focused on neurodegenerative diseases.